Selective CDK2 inhibitor developer advancing INX-315 for CDK4/6-resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors.
At a glance
- Founded: 2020
- HQ: RTP
- Sector: Biotech
- Stage: Series B
- Total raised: $47M
- Last round: Series B
Funding sources
Sources attached to recorded funding rounds.
See the full company record.
Founders, funding history and recent signals. Free accounts open immediately.
Listed roles
All Triangle rolesChecking listed roles…